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Mycoplasma bovis is a cell-wall-less bacterium and belongs to the class Mollicutes. It is
the most important etiological agent of bovine mycoplasmoses in North America and
Europe, causing respiratory disease, mastitis, otitis media, arthritis, and reproductive
disease. Clinical disease associated with M. bovis is often chronic, debilitating, and
poorly responsive to antimicrobial therapy, resulting in significant economic loss, the full
extent of which is difficult to estimate. Until M. bovis vaccines are universally available,
sanitary control measures and antimicrobial treatment are the only approaches that
can be used in attempts to control M. bovis infections. However, in vitro studies show
that many of the current M. bovis isolates circulating in Europe have high minimum
inhibitory concentrations (MIC) for many of the commercially available antimicrobials.
In this review we summarize the current MIC trends indicating the development of
antimicrobial resistance inM. bovis as well as the knownmolecular mechanisms by which
resistance is acquired.
Keywords: Mycoplasma bovis, minimum inhibitory concentrations, tetracyclines, macrolides, aminoglycosides,
fluoroquinolones, chloramphenicols, pleuromutilins
INTRODUCTION
Mycoplasma bovis is a cell-wall-less bacterium and belongs to the classMollicutes (Razin, 1978). It
is the most important etiological agent of bovine mycoplasmosis in North America and Europe,
causing respiratory disease, mastitis, otitis media, arthritis, and reproductive disease (Nicholas
and Ayling, 2003). Until M. bovis vaccines are universally available, sanitary control measures
and antimicrobial treatment are the only approaches that can be used in attempts to control
M. bovis infections. However,M. bovis is refractory to ß-lactams and to all antimicrobials that target
the cell wall. In addition, mycoplasmas are also naturally resistant to polymyxins, sulfonamides,
trimethoprim, nalidixic acid, and rifampin (Taylor-Robinson and Bebear, 1997). Antimicrobials
that are mycoplasmastatic provide an opportunity for the host’s immune response to develop and
counteract infection, butM. bovis has defense mechanisms that include an ability to vary its surface
proteins (Lysnyansky et al., 1996) and form biofilms (McAuliffe et al., 2006).
The potential effectiveness of antimicrobials in vivo can be assessed by in vitro susceptibility
testing to determine theminimum inhibition concentration (MIC). Guidelines for in vitro testing of
veterinary mycoplasma species have been published (Hannan, 2000). However, the data produced
are subject to interpretation as there are currently no in vitro testing standards and interpretive
breakpoints have not been determined. Standards for testingMollicutes that cause clinical infections
in humans Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum have
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been published (Waites et al., 2012). However, the growth
requirements of these species differ from those of M. bovis. In
addition, the authors are not aware of specific publishedM. bovis
pharmacokinetics (PK)/pharmacodynamics (PD) studies which
can influence the interpretation of in vitro antimicrobial
sensitivity.
Herein, we review in vitroMIC data that indicate thatM. bovis
is developing antimicrobial resistance, which is increasingly
being supported by molecular evidence of genetic mutations
consistent with antimicrobial resistance and by reports of
treatment failure.
ANTIMICROBIAL CLASSES ACTIVE
AGAINST M. BOVIS
Control of M. bovis infection requires early identification
and treatment with antimicrobials including the tetracyclines,
macrolides and some fluoroquinolones. However, few are
specifically approved for treating M. bovis in cattle and
with the exception of the fluoroquinolones, which are
mycoplasmacidal, and the aminoglycosides, which are
mycoplasmacidal at high concentrations, the remaining
antimicrobials are mycoplasmastatic, and generally work
by inhibiting protein synthesis. The typical tetracyclines,
chlortetracyline and doxycycline which are polycyclic structures
of the perhydronaphthacene carboxamide inhibit protein
synthesis in the ribosome by binding to the 30S ribosomal
subunit and blocking an attachment of aminoacyl-tRNA to the A
site (Bryskier, 2005a). Other plasmid related resistance, or eﬄux
mechanisms present in some Mycoplasma species have not been
described inM. bovis.
The macrolides which are known to be good for treating
respiratory infections have been shown to have a preferential
distribution in vivo, concentrating in diseased lungs, up to
three times the concentration detected in healthy lungs (Reeve-
Johnson, 1999). Macrolides are hydrophobic molecules that
have a central 12-16-membered-ring lactone with few or
no double bonds. They inhibit protein synthesis possibly
by preventing peptidyltransferase from adding the growing
peptide attached to tRNA to the next amino acid as well as
inhibiting ribosomal translation. Another potential mechanism is
premature dissociation of the peptidyl-tRNA from the ribosome.
Macrolides can penetrate phagocytic cells thereby allowing
treatment of intracellular infections. Lincosamides consist of an
amino acid and a sugar connected by an amide bond. They act on
the 50S subunit of the ribosome, preventing transpeptidation by
inhibiting peptidyl-transferase.
The fluoroquinolones are synthetic antimicrobials and all
have a pyridine-ß-carboxylic nucleus. Their activity depends on
several factors: the aromatic system associated with the pyridine-
ß-carboxylic acid nucleus, the substituents, and their spatial
disposition. These substituents produce greater affinity for the
target enzymes (DNA gyrase and topoisomerase IV) but also
allow penetration of the bacterial outer membrane (Bryskier,
2005b). The activity of these antimicrobials can be affected by pH,
magnesium and calcium ions.
The aminoglycosides are amino sugars and fall into two
broad groups based on their chemical structures: streptomycin
and its derivatives and deoxystreptamines. The ribosome is the
prime target of their action, but other actions on membranes
and modifications of RNA synthesis have been observed. They
are considered mycoplasmacidal, but that is concentration
dependent.
The phenicols are derived from dichloroacetic acid with an
aromatic nucleus and an alkyl group and an aminopropanediol
chain. The fluoro derivative of chloramphenicol, florfenicol,
is commonly used in the veterinary field. It inhibits protein
synthesis by binding to the 50S ribosomal subunit inhibiting the
peptidation reaction and the translation of bacterial mRNA.
Pleuromutilins, such as tiamulin and valnemulin are
semisynthetic derivatives that have a tricyclic diterpenoid
structure with different side chains. They have been used in
veterinary medicine; they bind to the peptidyl transferase
component of the 50S ribosomal subunit to inhibit protein
synthesis (Long et al., 2006). Tiamulin was the first pleuromutilin
compound to be approved for veterinary use in 1979, followed
by valnemulin in 1999 (Novak and Shlaes, 2010).
M. BOVIS IN VITRO SUSCEPTIBILITY
PROFILES AND TRENDS
M. bovis treatment failures are increasingly being associated
with antimicrobial resistance. However, different research groups
report variations in the proportion of M. bovis isolates with
decreased susceptibility. This may be related to geographical
origin, year of isolation, type of livestock production system,
clinical presentation, or site of isolation of the strains tested.
However, this may also indicate differences among the countries
in regulatory practices for use of antimicrobials. Not all studies
included epidemiology or typing of M. bovis isolates, but those
which did, reported that in some countries the acquisition of
resistance to antimicrobials in M. bovis was attributed to the
emergence and spread of a single clone (Becker et al., 2015)
while in other the genetic heterogeneity ofM. bovis isolates with
decreased susceptibility was identified (Lysnyansky et al., 2009).
M. bovis susceptibility testing has a role in epidemiological
monitoring of acquired resistance and can guide the veterinarian
in the selection of the most likely effective antimicrobial
treatment, but published MIC data requires some interpretation,
as there is no agreed standard method or controls for
susceptibility testing of M. bovis. Although guidelines were
produced by Hannan (2000), variations in the growth and
approaches to determining the endpoint by different laboratories
are reported and make it hard to compare results from
different laboratories. However, these differences do not detract
from the trends observed, which are now being supported
by genetic evidence of resistance correlated with high MIC
values (Lysnyansky et al., 2009; Sato et al., 2013; Lerner et al.,
2014; Amram et al., 2015; Khalil et al., 2015). Nevertheless,
standardized methods, controls and breakpoint interpretations
would be highly beneficial for future epidemiology assessment of
antimicrobial sensitivities and treatment guidance. In Table 1 we
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TABLE 1 | Minimal inhibitory concentration ranges (µg/ml) and MIC50 and
MIC90 ranges for various antimicrobials against M. bovis
a.
Antimicrobials MICb Range MIC50 Range MIC90 Range
Tetracyclines
Tetracycline <0.03–>64 1–8 4–64
Oxytetracycline 0.05–128 2–128 4–128
Chlortetracycline 0.25–256 2–128 2–256
Doxycycline ≤0.03–1 0.5 1
MLSK Group
Erythromycin 4–>512 >3.2–512 32–512
Tylosin 0.2–>256 1–>128 6.25–>128
Tilmicosin ≤0.5–>512 2–512 4–>512
Gamithromycin 128–>128 128 128
Tildipirosin 128–>128 128 128
Tulathromycin ≤0.063–>128 0.25–128 8–>64
Kitasamycin 1–128 4 64
Josamycin 0.78–12.5 1.56 6.25
Spiramycin 0.39–>100 3.12 25
Lincomycin 0.06–>256 0.78–>64 3.12–>64
Clindamycin 0.03–>256 0.5–8 >32
Pirlimycin <0.125–0.5 0.25 0.5
Pleuromutilins
Tiamulin <0.03–2 0.06–0.2 0.78–1
Valnemulin <0.03 <0.03 <0.03
Fluoroquinolones
Enrofloxacin 0.025–>32 0.12–1 0.12–32
Danofloxacin 0.078–32 0.156–0.5 0.312–8
Marbofloxacin 0.25–>32 0.625–1.25 0.625–32
Flumequine 16–128 64 128
Ciprofloxacin 0.125–1 0.5 1
Aminoglycosides
Gentamycin 2–>64 8 32
Kanamycin 8–>128 32–64 64–>128
Aminocyclitol
Spectinomycin 0.03–>256 1–>256 2–>256
Chloramphenicols/Phenicols
Chloramphenicol 0.25–>32 2–8 2–32
Thiamphenicol 3.12–>512 6.25–>512 12.5–>512
Florfenicol 0.06–64 1–8 2–32
aThe data are compiled from multiple published studies (Ayling et al., 2000; Hirose et al.,
2003; Thomas et al., 2003; Rosenbusch et al., 2005; Godinho, 2008; Gerchman et al.,
2009; Uemura et al., 2010; Soehnlen et al., 2011; Kroemer et al., 2012; Hendrick et al.,
2013; Ayling et al., 2014; Gautier-Bouchardon et al., 2014; Kawai et al., 2014; Sulyok
et al., 2014; Kong et al., 2016) in which different methodologies (microbroth and agar
dilution, but not E-test) and different antimicrobial concentrations were used (adapted
from Bebear and Kempf, 2005; Waites et al., 2014).
bOnly MIC data obtained for M. bovis isolated after 1990 were included.
present the susceptibility profiles (ranges of MICs, MIC50, and
MIC90), obtained by microdilution and agar dilution methods,
of M. bovis isolated in different countries since 1990. Both
the MIC50 and MIC90 may indicate shifts in the susceptibility
of bacterial populations to antimicrobials since MIC50 values
show the general potency of an antimicrobial against a specific
type of bacteria, while the MIC90 values indicates the potential
and first stages of specific bacteria developing resistance to an
antimicrobial.
Tetracyclines
In vitro susceptibility data from all over the world reveal
heterogeneity in the susceptibility pattern to tetracyclines with
MIC50 values for oxytetracycline ranging from 2 to <8µg/ml
for isolates from Belgium, North America and Israel (Thomas
et al., 2003; Rosenbusch et al., 2005; Gerchman et al., 2009;
Soehnlen et al., 2011; Hendrick et al., 2013); while the MIC50
of isolates from the UK, the Netherlands, France, Hungry and
Japan (Ayling et al., 2000, 2014; Hirose et al., 2003; Uemura
et al., 2010; Gautier-Bouchardon et al., 2014; Kawai et al., 2014;
Sulyok et al., 2014) was reported to be ≥8µg/ml. Notably,
when susceptibility to tetracyclines was tested in two cohorts
of respiratory M. bovis isolates isolated in the UK in 2004 and
2009, a significant increase in the MIC50 from 1 to 32µg/ml was
identified (Ayling et al., 2014). In contrast, in France, the group of
archived isolates (1978–1979) already demonstrated high MIC50
to oxytetracycline (32µg/ml), which increased to ≥32µg/ml in
recent isolates (2010–2012) (Gautier-Bouchardon et al., 2014).
The authors suggested that less susceptible M. bovis isolates had
developed by 1978–1979.
Macrolides and Lincosamides
Acquired resistance to macrolides in M. bovis is a widely
known phenomenon and isolates with high MICs are frequently
identified (Table 1). For example, MIC50 values of ≥32µg/ml
for tilmicosin alone or for tylosin and tilmicosin were identified
in recent British and Hungarian isolates (Ayling et al., 2014;
Sulyok et al., 2014) as well as in isolates from western Canada,
Japan and the USA (Rosenbusch et al., 2005; Uemura et al.,
2010; Hendrick et al., 2013; Kawai et al., 2014). All recent
French isolates hadMICs of≥64µg/ml for tylosin and tilmicosin
(Gautier-Bouchardon et al., 2014). Gerchman et al. (2009)
reported marked differences in susceptibility profiles to tylosin
and tilmicosin in isolates from different geographical regions.
Israeli isolates were significantly more resistant to macrolides
than isolates from calves imported from Hungary (2005–2007).
However, recent Hungarian isolates (2010–2013) are more
resistant to these antimicrobials (MIC50 andMIC90 ≥128µg/ml)
(Sulyok et al., 2014). Such data emphasize the requirement for
periodic antimicrobial susceptibility testing on a regional basis.
Both archived and recent French isolates possessed high
MICs for the new-generation macrolides, gamithromycin
and tildipirosin. In addition, all tested French isolates and
27% of British tested isolates had MIC values of ≥128µg/ml
to tulathromycin, a relatively new semi-synthetic macrolide
(Ayling et al., 2014; Gautier-Bouchardon et al., 2014).
Interestingly, results of a susceptibility study comparing
MICs for tulathromycin in M. bovis respiratory isolates isolated
in Europe prior to 2002 and between 2004 and 2006 showed an
increase in MIC50 (from 0.25 to 4µg/ml) without a change in
the MIC90 (>64µg/ml) (Godinho, 2008). The authors suggested
that a high MIC does not necessarily reflect a lack of clinical
efficacy of tulathromycin since an isolate with an MIC >64µg
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/ml was effectively treated in an experimental trial (Godinho
et al., 2005; Godinho, 2008).
The MIC50 for lincomycin ranged from 0.78 to ≥64µg/ml in
several studies (Hirose et al., 2003; Thomas et al., 2003; Uemura
et al., 2010; Ayling et al., 2014; Sulyok et al., 2014) and MIC50 of
0.19µg/ml (but with MIC90 of >256µg/ml; tested by E-test) for
clindamycin were reported from Canada (Francoz et al., 2005).
Interestingly, Ayling et al. (2014) reported decreased MIC50
values for lincomycin (from 8 to 1µg/ml) and clindamycin (from
≥32 to 0.25µg/ml) in M. bovis isolates isolated in the UK in
2004 and 2009. Low MIC50 and MIC90 of 0.25 and 0.5µg/ml,
respectively for pirlimycin (Table 1) were reported in one study
from Japan (Kawai et al., 2014).
Fluoroquinolones
In contrast to acquired resistance to macrolides which has
been reported for a long time, the resistance to veterinary
fluoroquinolones is a relatively new phenomenon. For example,
only a single fold increase in MIC50 and MIC90 (in both
cases from 0.25 to 0.5µg/ml for enrofloxacin and danofloxacin;
and from 0.5 to 1µg/ml for marbofloxacin) was reported
between 1978–1979 and 2010–2012 for French isolates (Gautier-
Bouchardon et al., 2014). The same increase in the MIC50 was
also found in UK isolates isolated between 2004–2005 and during
2007–2009. However, their MIC90 values differed considerably
(0.5−1 vs. 8− >32µg/ml) (Ayling et al., 2014). Relatively low
enrofloxacin MIC50 values of 0.12 to 0.5µg/ml were reported
in North America, Japan and some European countries (Hirose
et al., 2003; Thomas et al., 2003; Rosenbusch et al., 2005; Uemura
et al., 2010; Soehnlen et al., 2011; Hendrick et al., 2013; Gautier-
Bouchardon et al., 2014; Kawai et al., 2014; Sulyok et al., 2014).
This may reflect differences in therapeutic use of antimicrobials
in different countries.
Aminocyclitol and Aminoglycosides
Several studies have demonstrated relatively low MIC50 and
MIC90 values for spectinomycin (up to 8µg/ml) (Rosenbusch
et al., 2005; Uemura et al., 2010; Hendrick et al., 2013), while
others reported that the difference between the MIC50 (1–
8µg/ml) and MIC90 (>32µg/ml) was high (Ayling et al., 2000,
2014; Thomas et al., 2003; Soehnlen et al., 2011; Sulyok et al.,
2014). In addition high MIC50 and high MIC90 (≥256µg/ml)
values for spectinomycin were also reported (Ayling et al., 2000,
2014; Thomas et al., 2003; Soehnlen et al., 2011; Sulyok et al.,
2014). Interestingly, higher spectinomycin MIC values have been
reported for isolates frommilk. Rosenbusch et al. (2005) reported
that 6 out of 14 USA milk isolates had MIC values >16µg/ml
while Soehnlen et al. (2011) reported a significant difference
between MIC50 of milk (>256µg/ml) and lung (8µg/ml)
isolates. MIC values for gentamycin ranged from 2 to >64µg/ml
(Thomas et al., 2003; Sulyok et al., 2014) and kanamycin from 8
to >128µg/ml (Uemura et al., 2010; Kawai et al., 2014).
Chloramphenicols
The MIC50 values for florfenicol ranging from 1 to 8µg/ml were
identified in North America, Europe and China (Rosenbusch
et al., 2005; Soehnlen et al., 2011; Hendrick et al., 2013; Kong
et al., 2016). In addition,M. bovis isolates from Japan gave MIC50
values of 6.25-8µg/ml and 6.25->512µg/ml to chloramphenicol
and thiamphenicol, respectively (Hirose et al., 2003; Uemura
et al., 2010). Due to the potential toxicity of phenicols and
chloramphenicols (not florfenicol), their use is now illegal in food
animals in many countries (Papich and Riviere, 2013).
Pleuromutilins
The few MIC studies on tiamulin and valnemulin showed low
MIC values for both antimicrobials (Table 1; Thomas et al., 2003;
Gautier-Bouchardon et al., 2014). The efficacy of valnemulin
against M. bovis infection was also demonstrated in vivo
(Stipkovits et al., 2001, 2005).
MOLECULAR MECHANISMS OF IN VIVO
ACQUIRED RESISTANCE BY M. BOVIS
In general, until now, the only mechanisms of acquired in vivo
resistance described in Mollicutes are target modification and
ribosome protection by the tet(M) determinant (Bebear and
Kempf, 2005).
Tetracyclines
The genetic background for decreased tetracycline susceptibility
has been elucidated in greater detail in mycoplasmas of human
origin than in M. bovis (reviewed by Waites et al., 2014).
Ribosomal protection by tet(M) determinants in M. hominis
and Ureaplasma spp. tetracycline-resistant isolates was identified
(Roberts et al., 1985, 1986) while target modification with
point mutation(s) in the 16S rRNA genes was described for
in vitro obtained mutants of M. pneumoniae with MICs of
≤2µg/ml (Degrange et al., 2008). Recent correlation between
decreased susceptibility to tetracycline hydrochloride in M.
bovis isolates and mutations identified in the primary binding
pocket for tetracycline (Tet-1 site) located in 16S rRNA-encoding
genes (rrs3 and rrs4 alleles) was shown (Amram et al., 2015).
An increase in MICs to tetracycline (MICs ≥2µg/ml) was
correlated with the number of mutated nucleotide positions
within the Tet-1 site. Indeed, decreased susceptibilities to
tetracycline were associated with mutations present at two
(A965 and A967; E. coli numbering) or three positions (A965,
A967, and G1058) in the two rrs alleles. No tet(M), tet(O), or
tet(L) determinants were identified in any of the 70 M. bovis
isolates tested. Notably, no M. bovis isolates with high MICs
(≥32µg/ml) to tetracycline were available and tested in this
study.
Macrolides and Lincosamides
Macrolide resistance in mollicutes, which have 1–3 ribosomal
operons, is caused by point mutations of the macrolide-binding
site located in the 23S rRNA genes or in the genes encoding
ribosomal proteins L4 and L22 (reviewed by Waites et al.,
2014). Recently, M. bovis decreased susceptibility to tylosin and
tilmicosin was attributed to any one of the point mutations
G748A, C752T, A2058G, A2059G, or A2059C (E. coli numbering)
identified in one or both alleles of the 23S rRNAs (Lerner
et al., 2014). The data revealed that a combination of mutations
in two domains (II and V of 23S rRNA) was necessary to
achieve higher MICs (≥128µg/ml) to tylosin, while a single
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mutation in one of the domains could be sufficient to cause
a decrease in susceptibility to this antimicrobial. In that study,
amino acid (aa) substitution L22-Q90H (E. coli numbering) was
also identified in 24 of 32 representative M. bovis isolates with
different MICs, but no clear correlation between this mutation
and decreased MICs to tylosin and tilmicosin was found. In
addition, multiple aa substitutions were identified in the L4
protein, including at positions 185–186 (positions 64 and 65
in E. coli), which are adjacent to the macrolide-binding site
(Lerner et al., 2014). However, the actual impact of L4 aa
substitutions is hard to define since they were identified in
isolates with various MICs, some of which also possessed nt
substitution/s within the macrolide binding site of 23S rRNA
gene/s. Clarification of the role of mutations at positions 90-L22
and 64/or 64-65-L4 in decreased macrolide susceptibility by M.
bovis is required.
Fluoroquinolones
The only mechanism of acquired fluoroquinolone resistance
described in Mollicutes is alterations within the quinolone
resistance-determining regions (QRDRs) of DNA gyrase
subunits GyrA and GyrB and/or topoisomerase IV subunits
ParC and ParE. However, an active eﬄux mechanism has also
been demonstrated in vitro (Raherison et al., 2002). Amino
acid substitution in the QRDR of GyrA (Ser83Phe) alone or
with concurrent mutation Asn84Asp in ParC was found in
M. bovis isolates with MICs to enrofloxacin ranging from
0.32–1.25 to 2.5–5µg/ml, respectively (Lysnyansky et al., 2009).
In another study, mutation Ser83Leu in GyrA was identified
in 32 isolates with MICs of 0.25–2µg/ml to enrofloxacin,
orbifloxacin and danofloxacin; mutations in Ser83Leu of GyrA
and Ser81Pro of ParC were present in three isolates (4–16µg/ml)
while mutations Ser83Phe in GyrA and Ser80Ile in ParC were
found in four isolates (8–16µg/ml) (Sato et al., 2013). The
mutations Ser83Phe in GyrA and Ser80Ile in ParC were also
identified in a Chinese M. bovis isolate with MICs ≥16µg/ml
to ciprofloxacin, levofloxacin, lomefloxacin and norfloxacin
(Mustafa et al., 2013). In addition, Sato et al. (2013) showed that
laboratory-derived fluoroquinolone-resistant mutants selected
from two isolates with Ser83Leu in GyrA possessed an aa
substitution Ser80Ile or Ser81Tyr in ParC. Results of both studies
(Lysnyansky et al., 2009; Sato et al., 2013) suggest a cumulative
effect of the mutations in GyrA and ParC on fluoroquinolone
resistance. Previously, in vivo acquired resistance by veterinary
mycoplasmas to the fluoroquinolones has been attributed to aa
changes at positions 80 or 84 in the ParC as well as positions 83
in the GyrA (Hirose et al., 2004; Le Carrou et al., 2006; Vicca
et al., 2007).
Aminoglycosides
No enzymes responsible for chemical modification of
aminoglycosides have been identified in the M. bovis genome.
However, decreased susceptibility to streptomycin in M. bovis
was associated with nt T at position 912 (E. coli numbering)
in the 16S rRNA genes (Konigsson et al., 2002), a position
converting to resistance in E. coli (Frattali et al., 1990).
In an aminocyclitol antimicrobials, spectinomycin, isolates
with high MIC (>512µg/ml) were found to exhibit a C to A
transition at position 1192 (E. coli numbering) either in rrs3 or
in both rrs alleles (C. Schnee et al., abstract, IOM 2014, p. 60)
as has been previously shown for spectinomycin-resistant E. coli
(Sigmund et al., 1984).
Chloramphenicols and Pleuromutilins
To the best of our knowledge, no investigations of the phenicols
/chloramphenicols and pleuromutilins resistance mechanisms
forM. bovis have been published.
SUMMARY
Control ofM. bovis infections in cattle is inherently difficult. The
resulting clinical signs and disease are increasingly recognized as
having a significant adverse impact on animal welfare and the
economy of cattle farming around the world. Other than sanitary
preventative measures, treatment with antimicrobials is the only
approach for disease treatment. However, as emphasized herein,
the number of potentially effective antimicrobials is limited
as M. bovis lacks a cell wall. Among the few antimicrobials
licensed for treatment of M. bovis, there is increasing evidence
for resistance. Based on MIC levels and genetic analysis,
antimicrobial resistance by M. bovis to the tetracyclines,
macrolides, lincosamides, aminoglycosides, chloramphenicols,
and fluoroquinolones has been reported and appears to be
increasing. The mechanisms ofM. bovis antimicrobial resistance
have largely been based on genetic point mutations; few studies
have examined eﬄux mechanisms and no plasmids have so far
been detected inM. bovis.
This review highlights the necessity to agree a standardized
method and controls for animal mycoplasma antimicrobial
susceptibility testing. In addition breakpoints should be
determined and the use of molecular resistance markers could be
used to define them.
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